Ozone therapy activates antioxidant defenses, improves oxygen utilization, and modulates immune signaling. The strongest evidence sits in chronic infections, post-viral fatigue, and tissue oxygenation. It is not a stand-alone cure, but integrated rationally it earns a place in a serious protocol.

Ozone is a charged form of oxygen. When given medically in precise doses, it nudges the body's own defenses without damaging tissue — similar to how a controlled small stress trains the immune system.

At a Glance

Parameter	Detail
Mechanism	Reactive oxygen species (ROS) burst → hormetic redox signaling
Primary routes	Major autohemotherapy (MAH), rectal insufflation, ozonated saline
Strongest evidence	Chronic infection, diabetic wound healing, post-viral fatigue
Evidence level	RCTs limited; strong mechanistic + observational data
Typical frequency	10–20 sessions; 2–3×/week induction
Contraindications	G6PD deficiency, thrombocytopenia, active hyperthyroidism, pregnancy
Risk profile	Low when delivered by trained clinicians at therapeutic concentrations

Ozone therapy sits in an uncomfortable middle space: robust mechanistic science on one side, a deficit of large randomised controlled trials on the other, and an internet filled with both breathless enthusiasm and reflexive dismissal. Neither extreme serves patients well.

In clinical practice across chronic Lyme disease, post-COVID syndromes, and complex autoimmune presentations, I use ozone therapy as one tool within a broader protocol — not as a primary intervention, but as a modulator with a clear mechanistic rationale. What follows is an honest accounting of what the evidence actually supports.

How Ozone Works at the Cellular Level

Ozone (O₃) is an unstable triatomic form of oxygen. When it contacts biological fluids — plasma, blood, tissue exudate — it reacts within milliseconds to generate a controlled burst of reactive oxygen species (ROS) and lipid oxidation products called ozonides.

This might sound alarming. The key is dose and context.

At supraphysiological concentrations, ROS damage cells. At the calibrated sub-toxic concentrations used clinically (typically 20–80 µg/mL gas concentration), the same ROS pulse acts as a hormetic signal — a brief, low-level stress that activates protective cellular machinery rather than destroying it.

The downstream effects are well characterised in the basic science literature:

Nrf2 pathway activation: The master regulator of antioxidant gene expression is upregulated, increasing endogenous glutathione, superoxide dismutase, and catalase. This is the same pathway activated by fasting and high-intensity exercise.
2,3-DPG increase: Red blood cell 2,3-diphosphoglycerate rises, shifting the oxygen-haemoglobin dissociation curve rightward — meaning more oxygen is released to tissues at any given oxygen tension.
Cytokine modulation: Ozone-treated blood shows shifts in pro-inflammatory cytokines (IL-1β, TNF-α) alongside upregulation of anti-inflammatory mediators including IL-10 and TGF-β, consistent with an immunomodulatory rather than purely pro-inflammatory effect.
Platelet-activating factor inhibition: Relevant to the microclot pathology seen in post-COVID and Lyme-associated coagulopathy.

These are not theoretical effects. They are measurable in peripheral blood samples drawn before and after MAH sessions, and they form the scientific basis for the clinical applications discussed below.

Major Delivery Methods

Major Autohemotherapy (MAH)

MAH is the gold standard route for systemic effects. Approximately 100–200 mL of the patient’s blood is withdrawn into an IV bag, mixed with medical-grade ozone at a precise concentration, and re-infused. The whole cycle takes 30–45 minutes.

The advantage of MAH is that ozone never enters the body directly — it reacts with blood components ex vivo, and the ozonide-enriched blood then delivers the downstream signalling molecules systemically. This largely eliminates the pulmonary irritation risk associated with inhaled ozone and makes it far safer than direct gas insufflation into body cavities.

At our clinic, we use calibrated ozone generators with certified oxygen supply to ensure consistent gas concentrations on every session. This matters: the dose-response curve for ozone is narrow. Under-dose and you produce no biological effect; over-dose and you increase oxidative burden rather than hormetic benefit.

Rectal Insufflation

A less invasive option with reasonable bioavailability for the pelvic and portal circulation. Used when IV access is difficult, for gut dysbiosis support, or when patients are self-treating under medical supervision at home. The evidence base is thinner than for MAH but growing, particularly in IBD and rectal microbiome modulation studies.

Ozonated Saline

Intravenous ozonated saline has been evaluated in infection contexts. It delivers lower systemic ROS signalling than MAH but carries a simpler preparation profile. Some of the most compelling COVID-era data comes from Italian groups using ozonated saline alongside MAH protocols in hospitalised patients.

Where the Clinical Evidence Is Strongest

Chronic Wound Healing and Diabetic Ulcers

This is arguably where ozone therapy has the most consistent RCT-level support. A 2018 systematic review in the Journal of Dental Research and multiple wound-care trials demonstrate accelerated healing in diabetic foot ulcers, pressure injuries, and post-surgical wounds, with the mechanism attributed to both direct antimicrobial action and improved local tissue oxygenation.

For patients who don’t have chronic infections or metabolic disease, wound healing is not the relevant endpoint. But this evidence base validates the fundamental principle: ozone at the right dose improves oxygen delivery and modulates local inflammation.

Chronic Infections: Lyme, Biofilm-Associated Pathogens

Borrelia burgdorferi and co-infecting organisms — Bartonella, Babesia, Ehrlichia — share a feature that makes conventional antibiotic monotherapy inadequate for many patients: they form biofilms and persist within protected intracellular compartments. Ozone has demonstrated in vitro activity against spirochetes and multiple biofilm-forming organisms at concentrations achievable clinically.

The clinical translation is less clean — there are no large RCTs of MAH in chronic Lyme disease — but the observational data from European integrative clinics, including our own case series, shows consistent symptom improvement in patients with Herxheimer-like patterns following ozone sessions, consistent with pathogen-load reduction.

I combine MAH with biofilm-disrupting enzymes and agents to maximise pathogen accessibility before ozone exposure. The sequencing matters.

Post-COVID Syndromes

This is where ozone has attracted the most recent attention. The pathophysiology of post-COVID — microclot formation, mitochondrial dysfunction, neuroinflammation, and persistent viral antigen burden — maps well onto the mechanistic profile of ozone’s effects.

Tirelli and colleagues published a case series in 2020 showing improvement in post-COVID fatigue and oxygen saturation metrics following MAH courses. More importantly, the Italian group at Udine documented that ozone treatment in hospitalised COVID patients improved haematological parameters and reduced escalation to ICU compared to matched controls.

This is not RCT-level evidence. But given the mechanistic plausibility and the absence of effective conventional interventions for post-COVID, I consider it sufficient to support use within a structured post-COVID recovery protocol.

Autoimmune and Inflammatory Conditions

The immunomodulatory effects of MAH have been evaluated in rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Results are mixed. The clearest signal is in reducing inflammatory markers (CRP, ESR) and fatigue scores rather than disease-modifying effects on structural pathology. Ozone will not replace disease-modifying antirheumatic drugs in RA, but it can be a useful adjunct for symptom burden and immune recalibration.

What the Evidence Does Not Support

Intellectual honesty requires stating what is not supported:

Ozone is not an established cancer treatment. Some in vitro data show pro-apoptotic effects, but translating this to clinical oncology requires caution and RCT evidence that does not currently exist.
There is no reliable evidence that ozone therapy reverses neurodegenerative disease.
Claims of ozone therapy “detoxifying” heavy metals are mechanistically unsupported. If heavy metal burden is the clinical concern, EDTA or DMSA chelation has a more established evidence base.
Ozone administered incorrectly — wrong concentration, wrong route (never inhaled), wrong frequency — can cause oxidative damage rather than hormetic benefit. This is a treatment that requires clinician oversight.

Safety Profile and Contraindications

When delivered by trained clinicians using calibrated equipment, MAH has an excellent safety profile. The most comprehensive German registry data, covering tens of thousands of sessions, shows an adverse event rate below 0.0007% for serious complications.

Minor side effects are more common and include transient fatigue or headache in the first 24 hours (often indicating appropriate immune activation), mild IV-site discomfort, and occasional lightheadedness immediately post-infusion.

Absolute contraindications:

G6PD deficiency: Ozone-induced ROS can precipitate haemolytic crisis in G6PD-deficient patients. Screen before first session.
Severe thrombocytopenia (platelets < 50,000): Increased bleeding risk at IV sites.
Active hyperthyroidism: Ozone can transiently elevate thyroid hormone levels.
Pregnancy: Insufficient safety data; avoid.
Recent acute myocardial infarction: Wait minimum 6 weeks.

Relative contraindications requiring risk-benefit discussion: Anticoagulant therapy, haemophilia, immunosuppressive therapy for solid organ transplant.

For a full clinical breakdown of ozone risks stratified by administration route — including G6PD screening protocols, dose titration approach, and how to distinguish a Herxheimer-type oxidative response from a true adverse event — see Ozone Therapy Risks: A Physician’s Honest Assessment.

Integration Into a Clinical Protocol

Ozone therapy functions best as a component of a multimodal protocol rather than a standalone treatment. In our practice, the typical integration points are:

Infectious disease protocols: After initial antibiotic or antimicrobial herbal induction, MAH sessions 2–3× weekly support pathogen clearance, manage Herxheimer burden, and improve mitochondrial function. This is combined with vagus nerve support to maintain autonomic tone during the inflammatory response.
Post-COVID recovery: 10–15 MAH sessions over 6–8 weeks as part of a broader protocol addressing microclots, mitochondrial support, and neuroinflammation.
Longevity and performance: 1–2× monthly maintenance MAH as part of a broader oxidative medicine and NAD+ repletion protocol.

Session frequency tapers as clinical markers improve. I do not advocate for indefinite high-frequency ozone administration; the goal is to use the hormetic stimulus, observe the clinical and laboratory response, and adjust accordingly. Patients often ask how to choose between ozone and IV laser for their specific condition — for a structured clinical comparison including sequencing strategies, see Ozone vs. IV Laser Therapy: A Physician’s Comparison.

References

Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. 2009;29(4):646–682. PMID: 19148981
Elvis AM, Ekta JS. Ozone therapy: a clinical review. J Nat Sci Biol Med. 2011;2(1):66–70. PMID: 22470233
Franzini M, Valdenassi L, Ricevuti G, et al. Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported. Int Immunopharmacol. 2020;88:106879. PMID: 32932050
Re L, Martínez-Sánchez G, Bordicchia M, et al. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. Eur J Pharmacol. 2014;742:158–162. PMID: 25139736
Tirelli U, Franzini M, Valdenassi L. Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy. Eur Rev Med Pharmacol Sci. 2021;25(10):3669–3672. PMID: 34109592
Gulmen S, Kurtoglu T, Meteoglu I, et al. Ozone therapy as an adjunct to vancomycin enhances bacterial elimination in methicillin resistant Staphylococcus aureus mediastinitis. J Surg Res. 2013;185(1):64–69. PMID: 23462061
Sagai M, Bocci V. Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress? Med Gas Res. 2011;1:29. PMID: 22085506

Ozone Therapy Evidence: What the Clinical Research Actually Shows